Recon: Blueprint's $250M preclinical buy; WHO, CDC, Biden react to Omicron variant
ReconKari Oakes
APIsBiologics/ biosimilars/ vaccinesBiotechnologyCombination products/companion diagnosticsDiagnostics/IVDsGlobalMedical DevicesPharmaceuticalsReconKari OakesAPIsBiologics/ biosimilars/ vaccinesBiotechnologyCombination products/companion diagnosticsDiagnostics/IVDsGlobalMedical DevicesPharmaceuticals